Asthma Treatment Market Expected to Hit USD 38.3 Billion by 2033

Trishita Deb
Trishita Deb

Updated · Apr 10, 2024

SHARE:

At Market.us Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Learn more.
close
Advertiser Disclosure

At Market.us Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Our data is available to the public free of charge, and we encourage you to use it to inform your personal or business decisions. If you choose to republish our data on your own website, we simply ask that you provide a proper citation or link back to the respective page on Market.us Media. We appreciate your support and look forward to continuing to provide valuable insights for our audience.

Introduction

The Global Asthma Treatment Market is projected to grow significantly, from USD 26.1 Billion in 2023 to an estimated USD 38.3 Billion by 2033, exhibiting a Compound Annual Growth Rate (CAGR) of 3.9% during the forecast period. This growth can be attributed to various factors, including the increasing prevalence of asthma due to poor air quality and other environmental factors, heightened public awareness about the condition, and advancements in treatment methods. For instance, the development and high demand for monoclonal antibodies (mAbs) targeting specific cytokines and immunoglobulin E (IgE) represent a significant stride in treating chronic asthma cases not well managed by conventional drugs​.

Inhalers, particularly, dominate the treatment market due to their reliability, portability, and cost-effectiveness, alongside innovations that have led to advanced products like triple therapy inhalers for asthma and Chronic Obstructive Pulmonary Disease (COPD)​​. Moreover, the route of administration has seen a preference for inhaled medications due to their targeted delivery and minimized side effects​.

The market is also witnessing a trend towards personalized medicine, such as the use of combination therapies and biologics, to cater to individual patient needs and improve disease management. This shift towards customized treatment plans underscores the market’s move towards more effective and patient-centric solutions.

However, the market faces challenges, particularly in the affordability and accessibility of treatment. The high cost of asthma medications, including biologics and other advanced treatments, remains a significant barrier for many patients, potentially affecting adherence and outcomes. Yet, efforts are ongoing to make these treatments more accessible through generic versions and patient assistance programs​.

Recent developments have been marked by significant achievements, particularly by AstraZeneca. AstraZeneca’s Tezspire, a severe asthma therapy, has been approved in the EU with a new self-administration pen injector. It’s the first EU biologic therapy for severe asthma without phenotype or biomarker restrictions, potentially aiding 2.5 million patients globally. Phase studies showed a 92% success rate in self-administration. Tezspire could become a $1 billion product, outpacing sales predictions with $91 million in US sales in the first nine months of 2022​.

Teva’s “Pivot to Growth” strategy emphasizes innovation with a focus on high-value generics and innovative assets like an anti-TL1A in phase 2 for asthma, demonstrating potential in underserved markets​. The launch of digital inhalers, AirDuo® Digihaler® and ArmonAir® Digihaler®, marks a significant step in integrating digital technology into asthma management, enhancing patient and healthcare provider insights through data collection​. Financially, Teva reported a 10% increase in gross profit to $7,645 million in 2023, despite facing challenges such as inflation and exchange rate fluctuations. Research and development expenses rose by 14% to $953 million, reflecting investments in its innovative pipeline​. A strategic partnership with Alvotech aims to advance biosimilar products, highlighting Teva’s commitment to expanding its market reach​.

Key Takeaways

  • In 2023, the long-term control medication sector led the asthma treatment market significantly, securing 65.4% of the total market share.
  • The inhalation route of administration emerged as the foremost method, holding a commanding share of 53.8% in the global asthma treatment market.
  • Hospital pharmacies are the primary distribution channel for asthma treatments, maintaining a dominant market share of 59.4%.
  • The increasing incidence of respiratory diseases, including asthma, and swift product approvals have significantly propelled the market forward in recent years.
  • With a substantial revenue share of 51.2%, North America stands as the leading region in the global asthma treatment market for the year 2023.
Asthma Treatment Market Growth
To learn more about this report – request a sample report PDF

Asthma Treatment Statistics

  • Tezspire’s list price in the US is approximately $47,000 annually.
  • AUSTEDO® and AJOVY® expected to contribute to Teva’s annual revenue of over $2.5 billion by 2027.
  • UZEDY™ targets over 600,000 schizophrenia patients with a differentiated therapy profile.
  • Medication Adherence: Approximately 50% of asthma patients do not adhere to prescribed medication regimens, leading to poor symptom control and increased risk of exacerbations.
  • Effectiveness of Inhaled Corticosteroids (ICS): ICS, the mainstay of asthma treatment, reduce the risk of exacerbations by 50-60% and improve lung function by 15-20%.
  • Biologic Therapy Impact: Biologic therapies, such as omalizumab and mepolizumab, can reduce exacerbations by 50% in severe asthma cases not controlled by standard treatments.
  • Role of Immunotherapy: Immunotherapy, particularly sublingual immunotherapy (SLIT), has shown a reduction of asthma symptoms by up to 30% and a decrease in rescue medication usage by 40%.
  • Emergency Department Visits: Uncontrolled asthma results in approximately 2 million Emergency Department visits globally each year, with a significant economic burden on healthcare systems.
  • Healthcare Costs: The annual economic burden of asthma exceeds $80 billion globally, attributed to medical expenses, loss of productivity, and absenteeism from work or school.
  • Pediatric Asthma Management: Early diagnosis and appropriate management of pediatric asthma can reduce hospital admissions by 50% and significantly improve quality of life for children and their families.
  • Non-Pharmacological Approaches: Non-pharmacological interventions, such as smoking cessation programs and environmental control measures, have been shown to reduce asthma exacerbations by 30-50%.
  • Patient Education Impact: Patient education programs focusing on asthma self-management have been associated with a 50% reduction in hospital admissions and emergency room visits, enhancing overall disease control.
  • Global Impact: Asthma affected an estimated 262 million people in 2019 and caused 455,000 deaths. Most asthma-related deaths occur in low- and lower-middle-income countries.
  • India: Among India’s 1.36 billion people, about 35 million suffer from asthma. Underdiagnosis and inadequate treatment are significant challenges in the country.
  • Australia: In 2020–21, approximately $851.7 million was spent on asthma treatment and management, representing 0.6% of the total health system expenditure.
  • Australian Statistics: Just under 2.8 million (10.8%) people had asthma in 2022. About one in three (32.1%) people with asthma had a written action plan, and one in three (33.9%) used asthma medication daily.

Emerging Trends

  • AI and Data Analytics in Patient Monitoring: Artificial Intelligence (AI) and data analytics are set to revolutionize the management of chronic conditions, including asthma. Technologies that enable real-time health monitoring and predictive analytics are becoming more sophisticated, allowing for personalized treatment plans and proactive health management. Systems like Philips HealthSuite and products such as the OXOS Micro C handheld x-ray device, powered by AI, exemplify how advanced technologies can enhance diagnostic accuracy, improve patient monitoring, and facilitate early intervention. These innovations contribute to more efficient healthcare delivery and better patient outcomes​.
  • Wearables and Telemedicine: The integration of wearables and telemedicine in patient care is rapidly advancing. Devices equipped with AI-driven analytics, such as the Apple Watch with FDA-cleared ECG functions, illustrate the potential for remote patient monitoring and engagement. These technologies are expected to reshape interactions between patients and healthcare providers, with natural language processing and machine learning playing pivotal roles in symptom triage and personalized health plan development. The expansion of telemedicine and mobile health applications highlights a shift towards more accessible, personalized, and efficient healthcare services​.
  • Robotics in Healthcare: The integration of robotics into healthcare is providing innovative solutions for patient care, including asthma management. Robotics, augmented by AI, is enhancing surgical precision and decision-making, and similar principles are being applied to develop new devices and technologies for treating respiratory conditions. While robotics primarily finds application in surgery and rehabilitation, its potential in automating and refining complex medical procedures hints at future innovations that could directly or indirectly benefit asthma patients, such as automated delivery systems for inhaled medications or advanced diagnostic tools​.
  • 3D Printing for Personalized Medical Devices: 3D printing technology is reshaping the manufacturing of medical devices, including those used in the treatment of asthma. The ability to create custom-fit devices tailored to the specific needs of individual patients is one of the most promising aspects of 3D printing. This technology could lead to the development of personalized inhalers, spacers, and other asthma management tools that are more effective and comfortable for patients to use. The focus on personalization through 3D printing indicates a shift towards more individualized healthcare solutions, potentially improving adherence to treatment and overall patient outcomes​.
  • The Surge of Digital Health Solutions: The proliferation of digital health solutions, including mobile health apps and online patient support platforms, is providing asthma patients with more tools to manage their condition effectively. These digital solutions offer personalized tracking of symptoms, medication reminders, and telehealth consultations, enabling patients to take a more active role in their healthcare. The accessibility of digital health resources empowers patients with asthma to better understand their condition, leading to improved self-management and potentially reducing the need for emergency care. This trend towards digitalization in health care aligns with broader shifts in patient engagement and healthcare accessibility​.

Use Cases

  • Daily Management and Preventative Care: Patients typically utilize daily medication regimens to manage and prevent asthma symptoms. This includes the use of long-term control medicines such as inhaled corticosteroids, which reduce inflammation, and biologic medicines for difficult-to-control asthma. Controller medicines are vital in preventing asthma attacks and controlling chronic symptoms, allowing for a better quality of life​.
  • Quick-Relief Medications for Acute Attacks: For immediate relief during an asthma attack, quick-relief medicines, also known as relievers, are used. These include inhaled short-acting beta2-agonists (SABAs), which open the airways quickly, and oral corticosteroids to reduce airway swelling. It’s essential for patients to carry their quick-relief inhaler with them at all times for emergency use​.
  • Bronchial Thermoplasty for Severe Asthma: For patients with severe asthma that is not responsive to standard treatments, bronchial thermoplasty presents an alternative. This procedure involves applying heat to the airways’ muscles to reduce their thickness and prevent narrowing. Although this method can be effective, it comes with risks such as worsening asthma symptoms or the potential for airway infections​.
  • Creating an Asthma Action Plan: A critical aspect of asthma management is developing a personalized asthma action plan with a healthcare provider. This plan details how to recognize and avoid triggers, what to do during an asthma attack, which medicines to take and when, and emergency contact information. Such a plan empowers patients to manage their condition proactively​.
  • Monitoring and Adjusting Treatment: Asthma control can vary over time, necessitating regular monitoring and adjustment of treatment plans. This might involve at-home lung function tests using devices like peak flow meters or spirometers to measure lung capacity and airflow. Based on these measurements, healthcare providers can modify medication dosages or types to ensure optimal asthma control.
  • Lifestyle and Environmental Modifications: Alongside medical treatments, adjustments to lifestyle and environment can significantly impact asthma management. This includes identifying and avoiding known allergens or irritants, using air filters to reduce indoor allergens, and engaging in regular, moderate exercise to improve lung function. Education on the correct use of inhalers and adherence to treatment plans is also crucial​​​.

Key Players Analysis

  • AstraZeneca has marked a significant presence with its innovative solutions aimed at improving patient outcomes. Notably, the company’s product, Tezspire (tezepelumab-ekko), has been approved in the US for the add-on maintenance treatment of adults and pediatric patients aged 12 years and older with severe asthma. This approval, following a Priority Review by the US Food and Drug Administration (FDA), is based on the outcomes of the PATHFINDER clinical trial program. Another noteworthy product, Airsupra (albuterol/budesonide), formerly known as PT027, has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older. The FDA’s approval of Airsupra was influenced by results from the MANDALA and DENALI Phase III trials. These approvals underscore AstraZeneca’s commitment to addressing the complex needs of asthma patients through innovative therapeutic options​.
  • Teva Pharmaceutical Industries has notably contributed to the asthma treatment sector, exemplified by its development and FDA approval of CINQAIR® (reslizumab) Injection. This product is an interleukin 5 antagonist monoclonal antibody indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older, who exhibit an eosinophilic phenotype. The approval of CINQAIR® underscores Teva’s commitment to addressing the needs of patients with inadequately controlled severe asthma, offering them a new treatment option that targets the underlying causes of asthma exacerbations. Additionally, Teva has pursued innovative solutions like the Digihaler technology, the first smart inhaler system designed to aid in asthma management by providing objective data. These advancements highlight Teva’s role in pioneering treatments that leverage both biological understanding and technological innovation to improve patient outcomes in asthma care​​.
  • Sanofi-Aventis SA’s work in the asthma treatment sector is highlighted by Dupixent® (dupilumab injection), a leading medication for severe asthma related to type 2 inflammation. Clinically proven to reduce exacerbations, improve lung function, and decrease oral corticosteroid use, Dupixent® is approved in the EU, US, and Canada for patients inadequately controlled by conventional medications. Its mechanism, targeting key proteins IL-4 and IL-13 to combat inflammation, represents a significant advancement in treating severe asthma, emphasizing Sanofi’s commitment to innovative healthcare solutions​.
  • Mundi-Pharma has made significant strides in the asthma treatment sector, focusing on innovative drug delivery systems and combination therapies to enhance patient outcomes. A key development in their portfolio is the partnership with Vectura Limited for the global development and commercialization of VR2076, a novel inhaled triple therapy consisting of an inhaled corticosteroid (ICS), a long-acting beta2-adrenergic agonist (LABA), and a long-acting muscarinic antagonist (LAMA) in a single aerosol inhaler. This therapy aims to simplify dosing, improve patient compliance, and reduce exacerbations, with an anticipated market growth into a $3-5 billion class by 2025. Additionally, Mundi-Pharma has introduced the flutiform® K-Haler® device, a pressurized metered-dose inhaler with a breath-activated mechanism designed to ensure correct usage by patients. The K-Haler® seeks to address common issues of incorrect inhaler technique and poor adherence to therapy, critical factors in uncontrolled asthma​.
  • GlaxoSmithKline Plc (GSK) is a front-runner in asthma treatment, recently acquiring Aiolos Bio for $1.4 billion to enhance its respiratory biologics portfolio with AIO-001, a promising asthma medication. This acquisition aligns with GSK’s strategy to broaden its reach within the asthma patient community​​. GSK’s commitment to personalized asthma care is evident in its research efforts, notably in optimizing mepolizumab use for severe eosinophilic asthma treatment​​. Additionally, GSK’s comparative studies have shown mepolizumab’s effectiveness in reducing asthma exacerbations more efficiently than other treatments, positioning it as a leader in asthma care innovation​​. The company is also advancing GSK’294, a potential biologic for long-acting suppression of IL-5, indicative of GSK’s ongoing commitment to respiratory disease management and patient care improvement​.
  • Merck & Co., Inc., has made significant contributions to asthma treatment. One notable product is DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, which received approval from the U.S. Food and Drug Administration for patients 12 years of age and older. This approval highlights Merck’s commitment to addressing the needs of asthma patients through innovative treatments. DULERA combines an inhaled corticosteroid with a long-acting beta_2-agonist, designed to improve lung function in patients with persistent asthma. The clinical trials demonstrated significant improvements in lung function measures, underlining the product’s efficacy. Merck’s extensive history in advancing healthcare solutions further reinforces its position as a research-intensive biopharmaceutical leader, dedicated to bringing forth medicines that significantly impact healthcare professionals and patients alike​.

Conclusion

In conclusion, the global asthma treatment market is on a path of significant growth, driven by advancements in treatment options and an increasing awareness of the condition. Despite challenges related to the affordability and accessibility of advanced therapies, the development of personalized medicine and innovative delivery systems presents new opportunities for patient care. The emphasis on digital health solutions and patient-centric approaches is reshaping the landscape, promising better outcomes for those affected by asthma. As the market continues to evolve, the focus remains on overcoming barriers to treatment and enhancing the quality of life for patients worldwide.

SHARE:
Trishita Deb

Trishita Deb

Trishita has more than 7 years of experience in market research and consulting industry. She has worked in various domains including healthcare, consumer goods, and materials. Her expertise lies majorly in healthcare and has worked on more than 400 healthcare reports throughout her career.